Hospital
Hca Health Services of New Hampshire INC
Hca Health Services of New Hampshire INC was paid $10.80M by Medicaid between Jan 2018 and Dec 2024, across 142 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF NEW HAMPSHIRE INC
DERRY, NH 03038
DERRY, NH 03038
33aNPI1174570683assigned 05/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.80M
24GClaims207,212
24DCodes billed142
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Hampshire
Rank by total paid#5 of 9
Median peer was paid$10.80M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,329 | $1.77M | |
| 2019 | 42,723 | $1.96M | |
| 2020 | 34,168 | $1.73M | |
| 2021 | 38,854 | $1.99M | |
| 2022 | 30,492 | $2.03M | |
| 2023 | 11,040 | $789K | |
| 2024incomplete | 8,606 | $540K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 15,169 | 12,923 | $3.47M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 12,101 | 9,903 | $2.83M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 2,572 | 1,940 | $775K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 2,510 | 2,108 | $431K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.4% | 7,459 | 5,906 | $371K |
| G0378 | Hospital observation service, per hour | 3.4% | 1,329 | 584 | $365K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 2,166 | 1,591 | $286K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 1,769 | 1,422 | $274K |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.4% | 383 | 353 | $257K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 1,111 | 912 | $159K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 3,632 | 2,546 | $134K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 6,972 | 5,072 | $125K |
130 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,218 | $125K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,112 | $107K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,890 | $84K |
| 80053 | Comprehensive metabolic panel | <1% | 16,002 | $69K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 515 | $61K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,741 | $60K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,365 | $58K |
| 85027 | <1% | 20,009 | $48K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,016 | $44K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 297 | $43K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,819 | $43K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,598 | $42K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,317 | $34K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,554 | $31K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,895 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 172 | $28K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 484 | $26K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 297 | $25K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 91 | $21K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,691 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,738 | $19K |
| 84484 | <1% | 4,654 | $18K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 241 | $18K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 136 | $16K |
| 84703 | <1% | 3,810 | $12K | |
| 76830 | Ultrasound, transvaginal | <1% | 172 | $10K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 409 | $10K |
| 83880 | <1% | 913 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,022 | $9K |
| 83690 | <1% | 3,337 | $9K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 14 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,384 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,932 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 209 | $7K |
| 87040 | <1% | 1,535 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 193 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,143 | $7K |
| 83605 | <1% | 1,728 | $6K | |
| 81001 | <1% | 5,530 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 350 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,378 | $5K |
| 83735 | <1% | 2,100 | $5K | |
| 82077 | <1% | 636 | $5K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 189 | $5K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 448 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 327 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 318 | $5K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 247 | $4K |
| 73130 | <1% | 126 | $4K | |
| 87070 | <1% | 943 | $4K | |
| 85610 | <1% | 3,018 | $4K | |
| 73630 | <1% | 105 | $4K | |
| 73610 | <1% | 118 | $3K | |
| 96376 | <1% | 325 | $3K | |
| 80143 | <1% | 436 | $3K | |
| 85730 | <1% | 1,344 | $3K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 164 | $3K |
| 80179 | <1% | 434 | $3K | |
| 87186 | <1% | 769 | $3K | |
| 76801 | <1% | 34 | $3K | |
| 74018 | <1% | 137 | $3K | |
| 85379 | <1% | 626 | $3K | |
| 76770 | <1% | 37 | $2K | |
| 80076 | <1% | 590 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,841 | $2K |
| 80047 | <1% | 559 | $2K | |
| 93971 | <1% | 40 | $2K | |
| G0411 | Interactive group psychotherapy, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 114 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 150 | $2K |
| 73564 | <1% | 29 | $2K | |
| 86850 | <1% | 223 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 538 | $1K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 768 | $1K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 93 | $1K |
| 84702 | <1% | 148 | $1K | |
| 81003 | <1% | 2,361 | $1K | |
| 72100 | <1% | 57 | $1K | |
| 73030 | <1% | 35 | $1K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 33 | $1K |
| 87077 | <1% | 251 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 14 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,297 | $922.78 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 51 | $896.67 |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 163 | $878.11 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 16 | $862.52 |
| 86900 | <1% | 493 | $852.41 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 463 | $820.23 |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 219 | $810.68 |
| 86901 | <1% | 492 | $808.49 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 461 | $792.91 |
| 87807 | <1% | 170 | $783.51 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 656 | $756.01 |
| 86140 | <1% | 313 | $719.53 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,921 | $656.22 |
| 80061 | Lipid panel | <1% | 98 | $591.09 |
| 87400 | <1% | 96 | $537.46 | |
| A9270 | Non-covered item or service | <1% | 4,732 | $458.24 |
| 90715 | <1% | 29 | $437.03 | |
| 82550 | <1% | 179 | $428.87 | |
| 73110 | <1% | 13 | $373.56 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13 | $326.94 |
| 82728 | <1% | 41 | $305.94 | |
| 81002 | <1% | 187 | $297.37 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 326 | $271.80 |
| 87147 | <1% | 71 | $245.21 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 373 | $235.53 |
| 85651 | <1% | 116 | $191.29 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 499 | $175.76 |
| 84100 | <1% | 78 | $163.62 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 51 | $148.44 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 100 | $137.12 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 21 | $128.10 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 151 | $119.64 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 20 | $116.04 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 21 | $111.42 |
| J2704 | Injection, propofol, 10 mg | <1% | 125 | $102.17 |
| 83550 | <1% | 22 | $89.94 | |
| 83540 | <1% | 22 | $66.74 | |
| 81025 | <1% | 12 | $60.72 | |
| 87081 | <1% | 15 | $55.46 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31 | $54.24 |
| 82607 | <1% | 15 | $51.86 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 13 | $50.01 |
| 82150 | <1% | 16 | $48.80 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 107 | $46.29 |
| 82248 | <1% | 18 | $29.48 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 14 | $7.99 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 14 | $3.48 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUCAS, KERRIN (CFO)